Review Article

Targeting caspase-2 interactions with tau in Alzheimer’s disease and related dementias

Q1

STEFFEN POCKES a, b, c, * , MICHAEL A. WALTERS b , KAREN H. ASHE c, * , * a

a Institute of Pharmacy, University of Regensburg, Regensburg, Germany
b Department of Medicinal Chemistry, Institute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, Minnesota
c Department of Neurology, University of Minnesota, Minneapolis, Minnesota

A R T I C L E   I N F O

Abstract

Targeting amyloid-β plaques and tau tangles has failed to provide effective treatments for Alzheimer’s disease and related dementias (ADRD). A more fruitful pathway to ADRD therapeutics may be the development of therapies that target common signaling pathways that disrupt synaptic connections and impede communication between neurons. In this review, we present our characterization of a signaling pathway common to several neurological diseases featuring dementia including Alzheimer’s disease, frontotemporal dementia, Lewy body dementia, and Huntington’s disease. This signaling pathway features the cleavage of tau by caspase-2 (Casp2) yielding Δtau314 (Casp2/tau/Δtau314). Through a not yet fully delineated mechanism, Δtau314 catalyzes the mislocalization and accumulation of tau to dendritic spines leading to the internalization of AMPA receptors and the concomitant weakening of synaptic transmission. Here, we review the accumulated evidence supporting Casp2 as a druggable target and its importance in ADRD. Additionally, we provide a brief overview of our initial medicinal chemistry explorations aimed at the preparation of novel, brain penetrant Casp2 inhibitors. We anticipate that this review will spark broader interest in Casp2 as a target for restoring synaptic dysfunction in ADRD.

Q3

INTRODUCTION

The promise of discovering better treatments for Alzheimer’s disease and related dementias (ADRD), among the most feared and frequent causes of debilitation in the elderly, has eluded the valiant efforts of researchers worldwide. One reason for the lack of progress is that available interventions do not address the underlying pathophysiological mechanisms of these diseases, targeting putative pathological triggers rather than the processes that mediate their detrimental effects on the brain. Another reason is the recent recognition that most patients with dementia have multiple pathologies, potentially tempering the effects of single-target therapies. Therefore, the ability to target a unique signaling pathway that is present in multiple diseases is an increasingly important but unmet medical need. The development of therapies that repair synaptic connections and restore communication between neurons in the brain will undoubtedly improve the treatment of ADRD. There is an urgent need for better treatments since available interventions do not address the underlying mechanisms of these diseases.

Multiple experimental therapies targeting fibrillar amyloid-β (Aβ) plaques and tau tangles have failed to produce robust results. The tau protein undergoes a variety of posttranslational modifications in ADRD, resulting in the formation of tau fibrils. However, fibrillar tau has been dissociated from neuronal death and network dysfunction, implicating nonfibrillar species in mediating cognitive abnormalities. Targeting the nonfibrillar forms of Aβ and tau that are diffusely distributed throughout the brain, alone or in combination with antifibril therapies, may be a more successful strategy.

Caspase-2 – Role and function

Caspases (cysteine-dependent aspartate-directed proteases) are a group of proteases that cleave target proteins after aspartic acid

Abbreviations: Aβ, Alzheimer’s disease; ADRD, Alzheimer’s disease and related dementias; AMPAR, α amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; APP, amyloid precursor protein; ASO, antisense oligonucleotide; Asp, aspartic acid; Aβ, amyloid-β; BACE, β-site cleaving enzyme; CARD, caspase recruitment domain; Casp, caspase; Dab, 2 - 4-diaminobutyric acid; DED, death effector domain; ER, endoplasmic reticulum; FTD, frontotemporal dementia; HD, Huntington’s disease; LBD, Lewy body dementia; logP, logarithmic value of the partition coefficient; LTD, long-term depression; MDM2, mouse double minute 2 homolog; mEPSC, miniature excitatory synaptic current; PD, Parkinson’s disease; PDD, Parkinson’s disease with dementia; PS, presenilin; PTM, post-translational modification; SAR, structure-affinity relationship; Δtau314, tau cleavage product; TPSA, topological polar surface area

*Reprint requests Steffen Pockes, Institute of Pharmacy, University of Regensburg, Universitätsstraße 31, 93053 Regensburg, Germany
**Karen H. Ashe, Department of Neurology, University of Minnesota, 2101 6th Street SE, Minneapolis, MN, 55455

E-mail addresses: steffen.pockes@ur.de, spockes@umn.edu (S. POCKES), hsiao@umn.edu (K.H. ASHE).

https://doi.org/10.1016/j.trsl.2022.10.009
Received 22 July 2022; Revised 26 October 2022; Accepted 30 October 2022

1931-5244/© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Please cite this article as: S. POCKES et al., Targeting caspase-2 interactions with tau in Alzheimer’s disease and related dementias, Translational Research (2022), https://doi.org/10.1016/j.trsl.2022.10.009
Caspase-2 and tau in Alzheimer’s disease and related dementias

Caspases are activated by Aβ and caspase-2 has been shown to be required for Aβ1-42-induced cell death. These activated caspases cleave the neuronal protein tau, which is abnormally processed in AD. Caspase cleavage of tau is attributed mainly to Casp2, Casp3 and Casp6 producing tau fragments that have been shown in experimental models to induce neurodegeneration (Fig 1). However, it was recently demonstrated that Casp6 cleaved tau generates a potent secretagog that promotes aggregation, glial inflammation, or cognitive deficits. Casp2 was directly implicated as a key driver of synaptic dysfunction in J20 APP transgenic mice. This was proposed to be by activation of the RhoA/ROCK-II signaling pathway that leads to the collapse of dendritic spines via cleavage of ROCK-II.

Fig 1 shows a cartoon schematic of 2N/4R tau, indicating known sites of caspase cleavage. For clarity, post-translational modifications and cleavage by other proteases are not shown. Five sites of cleavage are known though there may be others that have not yet been detected. The tetrameric amino acid sequences for each of these sites are shown, along with a classification of the site as being a canonical or noncanonical site for Caspase-2. In general, Casp2 cleaves N-terminally to D-aa-aa-D (where aa = amino acid) sequences. Cleavage of tau at D13, D25, and D402 by caspase-2 has not been reported, but this has not been investigated fully. Four features of this schematic are noteworthy: (1) Cleavage at D421 by Casp1, Casp2, Casp3, Casp6, Casp7, and Casp8 has been well-characterized as leading to Δtau421. This tau fragment has been shown to form fibrillar filaments and tangles which have not been characterized. The cleavage of tau to give Δtau421 occurs at a noncanonical site for Casp2. We have shown that this fragment of tau is nonfibrillar, most likely because this cleavage is proximal to PHF6 which is considered essential for tau self-assembly. It is not known why this site is especially sensitive to Casp2 cleavage but binding of tau outside Casp2’s active site (exosites) may facilitate this cleavage; (2) Two other caspase cleavage sites are located near the N-terminus of tau and are canonical for both Casp6 and Casp3 cleavage. Notably, caspase cleavage at D348 is not observed, even though this sequence is canonical for both Casp2 and Casp3 and noncanonical for other caspases. It is possible that this proteolysis, and that at D13 and D25 occurs but is followed by other cleavage events that make it nonobservable.

**Fig 1** Sites in 2N/4R tau that have been observed to be cleaved by caspases. These results are typically observed in in vitro experiments with recombinant tau. (1) Asp421: cleavage site for Casp1, Casp2, Casp3, Casp6, Casp7, and Casp8. Cleavage here leads to fibrillar tau filaments and tangles. This is a canonical cleavage site (D-aa-aa-D, where aa = amino acid) for Casp2, 3, 7, 8 and a noncanonical cleavage site for Casp1. Casp2 cleaves tau at this site only in vitro. (2) Asp314: Casp2 cleavage site. Cleavage here results in the formation of Δtau314, a nonfibrillar form of tau. This is a noncanonical cleavage site. Casp2 cleaves tau at this site in vitro and in vivo. (3) Caspase cleavage sites in the N-terminal region of tau. Asp13: cleavage site for Casp6 (canonical). Asp25: cleavage site for Casp3 (canonical). (4) Although this is a canonical cleavage site for Casp2, 3, 7, 8, no cleavage at this site has been observed. Tau image based on Xia et al. 2016. Created with BioRender.com.
Our findings in Zhao et al suggest that tau and Casp2 form a toxic partnership. The 35kDa tau fragment generated when Casp2 cleaves tau at Asp314 (D314) enters the dendritic spine along with full-length tau, impairing synaptic function. The identification of D314 as the site at which Casp2 cleaves tau to form Δtau314 was achieved by mass spectrometry. The ability of each of the 8 known caspases expressed in the brain was also tested, and only Casp2 generated a 35-kDa tau fragment, presumably recognizing the noncanonical cleavage sequence YKPVD314 in tau. To verify the assumption that Casp2 cleaves tau at D314, a tau variant in which D314 was mutated to glutamate (D314E) was prepared and shown to resist Casp2 cleavage, firmly supporting the hypothesis that Δtau314 is formed when tau is cleaved by Casp2.

The presence of Δtau314 correlates inversely with memory function in tau transgenic mice and is elevated in humans with Alzheimer’s disease or mild cognitive impairment. Δtau314 reversibly impairs cognitive and synaptic function in animal and cellular models of tauopathies. The mislocalization and accumulation of tau in dendritic spines mediate synaptic dysfunction independent of neurodegeneration. In cell cultures, tau containing the P301L mutation (tauP301L) mislocalizes and accumulates in dendritic spines, the principal loci of excitatory neurotransmission and synaptic plasticity which underlie learning and memory. Tau mislocalization resulted in decreased synaptic transmission due to the reduction of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPAR) in the spines. When D314 was mutated to glutamate (D314E) to prevent caspase cleavage, tauP301L no longer mislocalized to spines. TauP301L also failed to mislocalize to spines in neurons cultured from Casp2 null mice. Conversely, recombinant Δtau314 did localize to spines even in neurons lacking Casp2. These data indicate that Casp2 catalyzes the mislocalization and accumulation of mutant tau and the reduction of AMPAR in spines, and also excludes the possibility that other proteases besides Casp2 induce tau mislocalization.

Under physiological conditions, Casp2 reduces functional AMPAR in dendritic spines leading to long-term depression (LTD). LTD is a form of synaptic plasticity that weakens excitatory neurotransmission and underlies the physiological process of forgetting, an essential component of normal cognition that is carefully regulated by neural signals. Recent studies of human brain specimens in our group have revealed elevated levels of Casp2 and Δtau314 not only in AD, but also in Parkinson’s disease with dementia (PDD), Lewy body dementia (LBD), Huntington’s disease and frontotemporal dementia (FTD; here Δtau314 levels were elevated in the brains of rTg4510 (Zhao et al) and rT2 mice (Steuer et al), not in human brain specimens) (Fig 3). The elevated levels of Casp2 in these conditions suggest that the physiological Casp2-LTD signaling pathway is co-opted and overstimulated by pathological triggers in several neurodegenerative conditions, leading to excessive synaptic weakening and dementia. While neural signals activate the physiological Casp2-LTD pathway, the precise triggers that activate the pathological Casp2-LTD pathway are unknown. Ubiquitous features of neurodegenerative disorders such as oxidative stress, ER stress, and DNA damage have been shown to activate Casp2 and could contribute to its dysregulation. Under pathological conditions, the attenuation of excitatory postsynaptic neurotransmission is mediated by excessive Casp2 cleavage of tau leading to the accumulation of tau and reduction of AMPAR in dendritic spines. Whether the cleavage of tau by Casp2 plays a role in physiological LTD remains to be investigated. The hyperactivation of Casp2 weakens excitatory neurotransmission resulting in unregulated forgetting (Fig 3).

**Fig 2.** The current mechanistic understanding of the roles of Casp2 and tau in synaptic function. (1) Tau undergoes post-translational modification (PTM) and is released from microtubules. (2) PTM-tau is cleaved by active Casp2 to yield Δtau314. (3) Δtau314 catalyzes the movement of tau from the neuron into the dendrite thereby positively regulating calcineurin activity, (4) which in turn causes reversible internalization of AMPAR at the synapse. Under normal physiological conditions, neural signals regulate Casp2 activity leading to long-term depression (LTD). However, under pathological conditions various forms of cellular stress abnormally activate Casp2 independent of the neural signals leading to a dysfunctional, sustained LTD-like state that depresses excitatory neurotransmission. (5) Other proteases cleave tau leading to fragments with distinct mechanisms of action. Created with BioRender.com. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Targeting caspase-2 by developing selective inhibitors

The identification of Casp2 cleavage of tau as a common mediator of synaptic dysfunction and dementia augments the significance and importance of developing Casp2 inhibitors. From a medicinal chemistry perspective, extensive efforts are still needed to accelerate the discovery of effective drugs. Although several studies on Casp2 inhibitors have been published in recent years,55,56,57 elementary features such as oral availability and brain penetration have not yet been achieved. Our initial studies on the development of selective Casp2 inhibitors followed an approach based on the canonical but unselective Casp2 inhibitor AcVDVAD-CHO and the tau cleavage sequence YKPVD314.58 A set of 35 pentapeptide ligands provided helpful insights into structure-affinity relationships (SAR) and achieved maximum selectivity with AcVDV (Dab)D-CHO (pKi(Casp2) = 7.26) by introducing the amino acid Dab (2,4-diaminobutyric acid) at position 2 (selectivity factor of ∼30 over Casp3).58 Surprisingly, the pentapeptide AcYPKVD-CHO, derived from the tau cleavage site, showed no affinity for either Casp2 or Casp3.58 By systematically exchanging individual amino acid positions, the amino acid lysine at P4 and proline at P3 were thought to be responsible for this lack of activity.58

The development and expression of a series of recombinant tau mutants in an in vitro cleavage assay were consistent with these medicinal chemistry findings.58 In the search for new lead structures with excellent Casp2 selectivity and drug suitability, another approach was taken by our groups in Bresinsky et al.57 This approach featured the investigation of inhibitors based on cleavage sites specific to Casp2 in proteins other than tau.58 The cleavage sequences of Golgin-160,56,57 the protein transport protein Sec16A,55,56 transcription regulatory factor 1,56,57 mouse and human MDM2, respectively, showed the highest affinity (pKi(Casp2/cpCasp2) = 8.15/8.03) derived from the Ral GTPase-activating protein subunit alpha-1,55 and mouse double minute 2 homolog (MDM2, human and mouse)56 were selected on the reported specificity of Casp2 cleavage and the pentapeptides AcGESPD-CHO, AcWDRAID-CHO, AcQDTRD-CHO, AcADRDT-CHO, AcLDVDP-CHO, AcFDVDP-CHO, and AcTVKD-CHO were prepared.59 This extended peptide series included another 53 new truncated molecules forming tetra- and tripeptides, but these peptides did not demonstrate enhanced Casp2 selectivity or affinity. These results support the hypothesis that a 5-amino acid motif is required for efficient Casp2 inhibition.59 The inhibitors AcFDVDP-CHO (pKi(Casp2) = 6.40) and, interestingly, does not contain an aspartic acid at position P4,59 Crystal structures (Casp3) of AcTVK(Dab)D-CHO derived from an expanded AcTVKD-CHO-series confirmed that the P4-Thr is a good isostere for the P4-Asp and causes little change in protein conformation.59

Our subsequent study (Singh et al) went a step further, incorporating peptidomimetic moieties and unnatural amino acids with the aim of obtaining more bioavailable structures.63 To achieve this goal, known structural elements which enhanced selectivity and efficacy from previous SAR studies57,64,65 were combined. In addition, S-33q (Fig. 4) and R-33q, the pure P2 epimers of the previously published racemic 33q,55

Fig. 3. The Casp2/tau/Δtau314 cascade of events we propose to be involved in dementia. Cellular stress (typically in the form of ER stress, reactive oxygen, DNA damage, tau mutants such as taup301L, etc.) activates Casp2, which in turn increases levels of Δtau314. This leads to the internalization of AMPAR, synaptic weakening and, ultimately, forgetfulness and dementia in multiple neurodegenerative conditions. The successful development of drugs that inhibit Casp2 could halt this insidious cascade of events and restore cognition. Created with BioRender.com. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

Fig. 4. Structures of selective Casp2 inhibitors S-33q, compound 1, and compound 3, and the caspase prodrugs VX-765 (Casp1 inhibitor) and TRP601 (Casp2/3 inhibitor).
were synthesized and pharmacologically characterized. While R-33q did not demonstrate significant affinity for Casp2 and Casp3, S-33q exhibited significant affinity for Casp2 (pKᵢ = 7.89) with 70-fold Casp2/Casp3 selectivity. Alterations at amino acid positions P4 and P5 resulted in compound 3 (Fig 4) which had 794-fold Casp2 selectivity over Casp3 and Casp2 activity in the double-digit nanomolar range (pKᵢ = 7.40). Further modification of the reactive warhead from aldehyde to nitrile at position P1 to improve pharmacokinetic and dynamic properties led to compound 1 (Fig 4) which exhibited high affinity (pKᵢ = 8.12) and a promising selectivity profile in an in vitro caspase panel assay (123-fold selective towards Casp3 and >2000-fold selective towards Casp1, 6, 7, 9) and only weak activity towards the proteolytic enzymes thrombin and cathepsin B (IC₅₀ = 18,620 nM, selectivity >1600-fold). Especially the low activity to other cysteine proteases like cathepsin B is a promising feature for this class of inhibitors, regarding their specificity. Fig 5 shows the computationally predicted covalent docking (CovDock, Schrödinger) of compound 1 with the Casp2 apo-structure (ligand removed) from PDB:1PYO. Key interactions are shown. Although the aldehyde warhead is a prominent feature of the recently approved drug voxelotor for the treatment of sickle cell anemia and an excellent warhead in our early SAR studies, this reactive group is often considered undesirable due to its high electrophility and susceptibility to oxidative metabolism. In contrast, nitrile-based covalent inhibitors have also been clinically validated, are known for their safety and efficacy in humans and (eg, nirmatrelvir a covalent inhibitor of the SARS-CoV-2 main protease), and have been used successfully in other caspase inhibitors. Compound 1 is a covalent reversible Casp2 inhibitor with stronger potency and higher specificity than previously reported inhibitors. More advanced biological assays confirmed that compound 1 effectively inhibits Casp2-mediated cleavage of tau and blocks the production of Δτau314. Using cultured rat and mouse hippocampal neurons expressing tauP301S (a commonly used model of frontotemporal dementia), it was demonstrated that compound 1 prevented the disproportionate accumulation of tauP301S in dendritic spines. Lastly, in an experimental electrophysiological setup, it was shown that expression of tauP301S impairs mEPSC function of excitatory synapses, as determined by recording mEPSCs, and that compound 1 completely normalizes mEPSCs and rescues synaptic function. These results indicate that Casp2 mediates its pathological effects catalytically, paving the way for further efforts to develop small molecule Casp2 inhibitors to treat ADRD. Indeed, this structural evolution will be necessary because, given the high molecular weight (674.74 Da) and high TPSA (218.03 Å²) of compound 1, we do not expect it to enter the brain in significant amounts with these physicochemical properties.

**Summary & outlook**

The targeting of tau tangles in the treatment of ADRD has thus far been unsuccessful, warranting efforts to target other forms of tau. We expect that targeting the formation of Δτau314, a soluble fragment of tau, may be more fruitful. Several lines of evidence in humans and mice validate Casp2 as a target: (1) Lowering Casp2 improves memory, synaptic function and neurodegeneration in mouse models of 4 neurodegenerative disorders — Alzheimer's disease (AD), Huntington's disease (HD), Parkinson's disease (PD), and frontotemporal dementia (FTD); (2) In mice modeling FTD, reducing Casp2 levels ~35% (using a morpholino ASO) lowers brain levels of the pathological tau fragment, Δτau314, and reverses memory deficits within 6 weeks; Unfortunately, our attempts to produce ASO as therapeutics were clouded by unexpected challenges of toxicity. (3) Lowering Casp2 levels in these mice before neurons have died normalizes memory function; (4) Even when 50% of hippocampal CA1 neurons have died, lowering Casp2 levels partially restores memory function; (5) Casp2-resistant mutant tau with a D314E mutation delays memory loss and neurodegeneration in transgenic mice modeling FTD; (6) Brain levels of Casp2 and Δτau314 are elevated in patients with AD, HD, PD, and LBD.

In vitro systems used to elucidate the underlying pathophysiological mechanisms of in vivo observations have shown that: (1) Tau accumulates and AMPAR are reduced in the dendritic spines of cultured primary neurons expressing mutant tau, but these processes do not occur in neurons lacking Casp2; (2) Compound 1 prevents the accumulation of tau and reduction of AMPAR in the dendritic spines of mutant tau-expressing neurons; (3) Rendering tau resistant to Casp2 maintains AMPAR in the dendritic spines of neurons from mouse models of FTD.

The Casp2-LTD signaling pathway is a natural pathway that is dysregulated, rather than a potential artifact of an experimental disease model, as is the case in transgenic rodents with supra-abundant amyloid plaque deposition. It is therefore likely to be present in humans and clinically relevant. Because Casp2-LTD is a normal pathway, the misregulated pathway is likely not an unintended artifact of our experimental ADRD models, minimizing the possibility that a Casp2 inhibitor will target a mechanism that does not exist or plays only a minor role in the...
pathogenesis of actual ADRD in humans. In aggregate, these in vivo and in vitro findings suggest that uncontrolled, pathological activation of the
Casp2/tau/Δtau314 signaling pathway markedly weakens excitatory neurotransmission and exaggerates forgetting, and that a Casp2 inhibitor will improve synaptic function and cognition in patients with mild and moderate ADRD. Targeting the Casp2/tau/Δtau314 pathway can prevent and reverse cognitive decline.43,45,65 One exciting clinical implication is that a Casp2 inhibitor might not only improve the ability to learn and remember new information, but also recover lost memories by fortifying the synapses in engrams that are suppressed by reductions in AMPAR.79,80 We predict that Casp2 inhibitors have the potential to improve dementia in Alzheimer’s disease and several related dementia, which is an increasingly important consideration given that most patients have more than 1 pathology.81-83

Several improvements of current Casp2 inhibitors are needed. Foremost is bioavailability, specifically orally administered and brain penetrant Casp2 inhibitors that restore synaptic function and reverse memory deficits in mouse models of ADRD. Our findings thus far play an important role in the design of new peptidomimetic inhibitors. It is unlikely that we can design these compounds solely based on adherence to Lipinski’s Rule of 5 (molecular weight, logP, hydrogen bond donors/acceptors, TPSA, rotatable bonds).84 Challenges to blood-brain barrier penetration have been overcome in the area of kinase inhibitors which have been a notoriously difficult class of compounds to target to the brain.85 Additionally, the development of Casp2 inhibitors as prodrug compounds may be another promising approach; brain penetrant caspase inhibitors that are prodrugs already exist. For example, TRP601/ ORPHIA133563 (Fig 4), an irreversible inhibitor of Casp3 and Casp2 that is a prodrug of Δ2Me-TRP601 (IC50 (Casp2) = 7.4 nM, IC50 (Casp3) = 0.42 nM), protects the newborn rodent brain against excitotoxicity, hypoxia-ischemia, and perinatal arterial stroke with a 6-hour therapeutic time window and no adverse effects on physiological parameters.86 Furthermore, TRP601 did not significantly modify the activity of a broad panel of enzyme, peptide and nonpeptide receptors, nuclear receptors, ion channels or amine transporters at 10 μM.86 When administered intravenously (i.v.), TRP601 (1 mg/kg) rapidly entered the brain in adult rats (Tmax = 25 minutes; Cmax = 120 ng/mL), and no TRP601-related cytotoxic effects were observed when administered i.v. to adult dogs at doses up to 3 mg/kg/d for 14 days.86 Another example is VX-765 (Belnacasan) (Fig 4), an orally absorbed prodrug of desethyl-VX-765 (VXT-043198), a reversible covalent, potent Casp1 inhibitor.85,87 VX-765 has been tested in 2 phase II clinical trials (treatment resistant partial epilepsy, NCT01048255; psoriasis, NCT00205465) but has not advanced further.

The uncertainties associated with developing successful peptidomimetic drugs that are bioavailable and penetrate into the brain warrant adopting additional strategies built around structures other than peptides. One potential approach involves the development of small molecule fragments that are obtained by identifying Casp2 inhibitors in libraries containing molecules < 300 daltons that possess favorable physicochemical properties. Such fragments may be used as starting points to optimize pharmacokinetic and pharmacodynamic properties. This strategy has worked well in the development of BACE (β-site cleaving enzyme; an aspartic protease) inhibitors,88 and appears to have been successfully applied to Casp6.89 Optimizing such compounds regarding to structure-activity and structure-physical properties could ultimately lead to a brain-penetrant small molecule Casp2 inhibitor.

Overall, the biological data for Casp2 as a target in ADRD is clear and compelling, and the medicinal chemistry advances for development of Casp2 inhibitors are promising for eventual use in clinical trials. Given the ever-increasing number of patients with ADRD, intensive research in this area is a vital and critical goal.

NOTES

The authors are founders and shareholders of Myriel, Inc.

ACKNOWLEDGMENTS

Conflict of Interest: All authors have read the journal’s authorship statement. The authors disclosed all potential conflicts of interests. All authors have read the journal’s policy on disclosure of potential conflicts of interest and have disclosed any financial or personal relationship with organizations that could potentially be perceived as influencing the described research.

The authors were supported by NIH Grant R01AG0623199 (Ashe, Walters), R01AG60766 (Ashe), Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, Forschungsstipendium 436921318, Pockes), ADDF-Harrington Scholar Award (Repairing Neurotransmission in Alzheimer’s Disease and Related Disorders by Targeting Caspase-2, Ashe), Lucas Brothers Foundation (Caspase-2 Inhibitors to Reverse Cognitive Decline, Ashe).

The manuscript has been reviewed by and approved by all named authors. The authors thank Jessica Fuller for her contribution regarding Fig S5.

REFERENCES

Acta Neuropathol Commun 2019;7:1


